I encourage you to do a search of the Internet using this search

what causes prostate cancer to become neuroendocrine

Here are some information you would find

Neuroendocrine prostate cancer (NEPC) can arise from two main pathways: de novo, meaning it develops independently, or as a treatment-emergent form (t-NEPC) from pre-existing prostate adenocarcinoma. A key driver of t-NEPC is androgen deprivation therapy (ADT), which is used to treat prostate cancer by inhibiting the androgen receptor, leading to the cancer cells developing resistance and transforming into NEPC.

The purpose of ADT is to reduce the amount of testosterone, The surgery did the same thing, Though testosterone does get created other places in the body. Zytiga takes it a step further and reduces testosterone even more. Does that mean that it is more likely to cause neuroendocrine than Enzalutamide, I can’t say, but since it acts more like an ADT Then maybe it is not a better solution to move to Zytiga.

I’m not sure anybody has a real answer to this question.